Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › FDA Approves Rx/Dx Combination for Acute Myeloid Leukemia

FDA Approves Rx/Dx Combination for Acute Myeloid Leukemia

Apr 28, 2017
|
staff reporter

NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Novartis' acute myeloid leukemia drug Rydapt (midostaurin) in combination with chemotherapy alongside Invivoscribe Technologies' LeukoStrat CDx FLT3 Mutation Assay to identify patients who can receive the drug.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

  2. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

  3. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  4. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  5. Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.